The quiet disrupters: DNA-encoded and RNA-encoded antibodies

A new approach to streamlining biologics manufacturing could soon catch on--encoding the therapies in DNA or RNA, which enjoins the patient to produce the proteins in vivo. While the biggest upside may be the speed and low cost of production, as the first encoded biologics begin to read out, companies are also looking for improved PK, safety and convenience.

Encoded antibodies are making little noise, rarely getting top billing in most companies with pipelines of DNA or RNA products. But the handful of companies pushing the technology are positioning their encoded mAb candidates as opportunities for proof of concept and growth...